AR044075A1 - Antagonista de un receptor sensible al calcio - Google Patents
Antagonista de un receptor sensible al calcioInfo
- Publication number
- AR044075A1 AR044075A1 ARP040101388A ARP040101388A AR044075A1 AR 044075 A1 AR044075 A1 AR 044075A1 AR P040101388 A ARP040101388 A AR P040101388A AR P040101388 A ARP040101388 A AR P040101388A AR 044075 A1 AR044075 A1 AR 044075A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- alkyl
- integer
- value
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 229940123613 Calcium receptor antagonist Drugs 0.000 abstract 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- -1 ethyleneoxy group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Abstract
Un compuesto que posee una acción antagónica sensible al receptor de calcio, una composición farmacéutica que comprende el compuesto, particularmente se provee un antagonista a receptor de calcio y una droga terapéutica para osteoporosis. Reivindicación 1: Un compuesto representado por la fórmula (1), caracteriza porque: n es 0 ó 1; p es un entero de valor 1 a 3; R1 es un grupo hidroxilo, un grupo alcoxilo C1-6 ó RA, en donde RA es Rc-OC(=O)-alquileno(C1-4)-O- ó OH-NH- , en donde Rc es un grupo alquilo C1-6 o un grupo cicloalquilo C3-6; R2 y R3 son iguales o diferentes y cada uno es un átomo de hidrógeno, un grupo hidroxilo, un átomo halógeno, un grupo amino, grupo acilamino C1-7, un grupo haloalquilo C1-6, un grupo carboxilo, un grupo alcoxicarbonilo C1-6, un grupo alcoxilo C1-6, un grupo haloalcoxilo C1-6, un grupo alquilo C1-6, un grupo hidroxialquilo C1-6, un grupo acilamino(C1-7)-alquilo(C1-6), un grupo alquenilo C2-6, un grupo aralquilo, un grupo fenilo, grupo alquilamino C1-6, un grupo di(alquil C1-6)amino, un grupo alcoxi(C1-6)-alquilo(C1-6), un grupo mercapto, un grupo ciano, un grupo nitro, un grupo morfolino, un grupo piperidino o un grupo pirrolidino, o R2 y R3 forman un grupo etilenoxilo; X1 es -C=C-, -C=N-, un átomo de oxígeno o átomo de azufre; Z es -S-, -SO-, -SO2-, -(CH2)m1-O-, -O-(CH2)m1-, -(CH2)m2-NH-, -NH-(CH2)m2-, -(CH2)m3-N(CH3)-, -N(CH3)-(CH2)m3-, un grupo alquileno C1-4, -SO2-N(CH3)-, N(CH3)-SO2-, -NHCO-, - CONH- o un grupo alquenileno C2-4, en donde m1, m2 y m3 son cada uno un entero de valor 0 a 2; X2 es -C=C-, un átomo de oxígeno o un átomo de azufre; R4 es un grupo alquilo C1-6 o un grupo cicloalquilo C3-6; R5 es un átomo de hidrógeno o RB; en donde RB es un grupo acilo C1-7 opcionalmente sustituido por un grupo carboxilo; Y es un átomo de carbono o un átomo de nitrógeno; y R6, R7 y R8 son iguales o diferentes y cada uno es un átomo de hidrógeno, un átomo halógeno, un grupo alquilo C1-6, un grupo alcoxilo C1-6, un grupo haloalquilo C1-6, un grupo haloalcoxilo C1-6, un grupo carboxilo, un grupo hidroxilo, un grupo ciano, un grupo nitro, un grupo fenilo, un grupo cicloalquilo C3-6, un grupo di(alquilo C1-6)aminocarbonilo o un grupo hidroxialquilo C1-6, o R6 y R7 adyacentes se unen para formar -CH=CH-CH=CH-, -C(OH)=CH-CH=CH-, -CH=C(OH)-CH=CH-, -O-(CH2)k1-O-, -O-(CH2)k2- ó -(CH2)k3-, en donde k1 es un entero de valor 1 a 4, k2 es un entero de valor 2 a 5, k3 es un entero de valor 3 a 6, con la condición que cuando R2 y R34 son átomos de hidrógeno y n es 1, entonces Z debe ser un grupo distinto de -SO2-N(CH3)- en donde el átomo de azufre se une al anillo V y un átomo de nitrógeno se une al anillo w, una sal farmacéuticamente aceptable del mismo o una forma ópticamente activa del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003119131 | 2003-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044075A1 true AR044075A1 (es) | 2005-08-24 |
Family
ID=33308093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101388A AR044075A1 (es) | 2003-04-23 | 2004-04-23 | Antagonista de un receptor sensible al calcio |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US7304174B2 (es) |
| EP (3) | EP1619180B1 (es) |
| JP (1) | JP3751312B2 (es) |
| KR (1) | KR100696927B1 (es) |
| CN (2) | CN100577633C (es) |
| AR (1) | AR044075A1 (es) |
| AT (1) | ATE452121T1 (es) |
| AU (1) | AU2004232604C1 (es) |
| BR (1) | BRPI0407097A (es) |
| CA (1) | CA2513738C (es) |
| CL (1) | CL2004000868A1 (es) |
| CO (1) | CO5640091A2 (es) |
| CY (1) | CY1109880T1 (es) |
| DE (1) | DE602004024668D1 (es) |
| DK (1) | DK1619180T3 (es) |
| ES (1) | ES2337576T3 (es) |
| HR (1) | HRP20100042T1 (es) |
| IL (1) | IL169575A (es) |
| MX (1) | MXPA05007609A (es) |
| MY (1) | MY138734A (es) |
| NO (1) | NO20054868L (es) |
| NZ (1) | NZ541188A (es) |
| PE (1) | PE20050460A1 (es) |
| PL (1) | PL1619180T3 (es) |
| PT (1) | PT1619180E (es) |
| RU (1) | RU2315036C2 (es) |
| SI (1) | SI1619180T1 (es) |
| TW (1) | TWI329628B (es) |
| WO (1) | WO2004094362A1 (es) |
| ZA (1) | ZA200505587B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US20070155819A1 (en) * | 2004-02-06 | 2007-07-05 | Marquis Robert W Jr | Calcilytic compounds |
| WO2007124465A2 (en) * | 2006-04-20 | 2007-11-01 | Amgen Inc. | Stable emulsion formulations |
| WO2008121386A2 (en) | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| US8039514B2 (en) * | 2008-06-05 | 2011-10-18 | Asahi Kasei Pharma Corporation | Sulfonamide compounds and use thereof |
| ES2412408T3 (es) * | 2008-12-24 | 2013-07-11 | Daiichi Sankyo Company, Limited | Compuestos de indanilo |
| NZ593675A (en) * | 2008-12-24 | 2012-06-29 | Daiichi Sankyo Co Ltd | Cyclic amine compounds |
| WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
| WO2010103429A1 (en) * | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
| CN102365261A (zh) * | 2009-03-26 | 2012-02-29 | 日本烟草产业株式会社 | 制备羧酸化合物的方法 |
| WO2010113860A1 (ja) * | 2009-03-31 | 2010-10-07 | 第一三共株式会社 | ビフェニル－環状アミン化合物 |
| US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2435404A1 (en) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2643292A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| RU2013128950A (ru) * | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Замещенные циклопентилазины в качестве casr-активных соединений |
| WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| EP2643290A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| WO2014033604A1 (en) * | 2012-08-27 | 2014-03-06 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| IL263494B2 (en) | 2016-06-13 | 2024-01-01 | Syneurx Int Taiwan Corp | Use of lithium benzoate for treating central nervous system disorders |
| AU2020399030A1 (en) * | 2019-12-09 | 2022-06-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist compound and application thereof |
| KR20230106582A (ko) * | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| KR20230112609A (ko) * | 2020-09-18 | 2023-07-27 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 상염색체 우성 저칼슘혈증 타입 1(adh1)의 치료를 위한 트리페닐 칼시라이틱 화합물 |
| WO2024220796A1 (en) | 2023-04-21 | 2024-10-24 | Calcilytix Therapeutics, Inc. | Treatment of hypoparathyroidism using triphenyl calcilytic compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE633760A (es) * | 1963-06-18 | |||
| DD207203A1 (de) * | 1982-06-21 | 1984-02-22 | Peter Meisel | Verfahren zur herstellung von epoxypropylethern |
| DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
| US5276008A (en) * | 1990-08-09 | 1994-01-04 | Bayer Aktiengesellschaft | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones |
| KR100251995B1 (ko) * | 1991-08-23 | 2000-06-01 | 젠센 제임스 유. | 칼슘 수용체 활성 분자 |
| US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| BR9708632A (pt) | 1996-04-09 | 2000-01-18 | Nps Pharma Inc | Composto calcilìticos |
| ES2171839T3 (es) * | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| AR018177A1 (es) | 1998-04-08 | 2001-10-31 | Smithkline Beecham Corp | Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento. |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| US20020052509A1 (en) | 1998-04-08 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds and method of use |
| US6334338B1 (en) | 1998-07-02 | 2002-01-01 | Lucent Technologies Inc. | Sol gel process of making a fiber preform with removal of oxide particles |
| US6291459B1 (en) | 1998-08-12 | 2001-09-18 | Smithkline Beecham Corporation | Calcilytic compounds |
| US6335338B1 (en) | 1998-08-12 | 2002-01-01 | Smithkline Beecham Corporation | Calcilytic compounds |
| NZ510760A (en) * | 1998-10-23 | 2003-08-29 | F | Bicyclic nitrogen heterocycles |
| PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
| CA2382119A1 (en) * | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Fast-acting formulation components, compositions and laundry methods employing same |
| IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| MY159417A (en) | 2000-01-24 | 2017-01-13 | Smithkline Beecham Corp | Calcilytic compounds |
| US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| CN1582275A (zh) | 2000-07-21 | 2005-02-16 | 史密丝克莱恩比彻姆公司 | 钙拮抗化合物 |
| US6916956B2 (en) | 2000-08-11 | 2005-07-12 | Japan Tobacco, Inc. | Calcium receptor antagonist |
| AU2002230579A1 (en) | 2000-10-25 | 2002-05-06 | Smithkline Beecham Corp | Calcilytic compounds |
| AU2002239489A1 (en) | 2000-10-25 | 2002-05-21 | Smithkline Beecham Corporation | Calcilytic compounds |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
| JPWO2004106280A1 (ja) * | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
-
2004
- 2004-04-23 CA CA2513738A patent/CA2513738C/en not_active Expired - Fee Related
- 2004-04-23 MY MYPI20041512A patent/MY138734A/en unknown
- 2004-04-23 US US10/830,480 patent/US7304174B2/en not_active Expired - Lifetime
- 2004-04-23 MX MXPA05007609A patent/MXPA05007609A/es active IP Right Grant
- 2004-04-23 AT AT04729243T patent/ATE452121T1/de active
- 2004-04-23 SI SI200431348T patent/SI1619180T1/sl unknown
- 2004-04-23 CL CL200400868A patent/CL2004000868A1/es unknown
- 2004-04-23 BR BR0407097-6A patent/BRPI0407097A/pt not_active IP Right Cessation
- 2004-04-23 WO PCT/JP2004/005886 patent/WO2004094362A1/ja not_active Ceased
- 2004-04-23 EP EP04729243A patent/EP1619180B1/en not_active Expired - Lifetime
- 2004-04-23 KR KR1020057013977A patent/KR100696927B1/ko not_active Expired - Fee Related
- 2004-04-23 PT PT04729243T patent/PT1619180E/pt unknown
- 2004-04-23 PE PE2004000403A patent/PE20050460A1/es not_active Application Discontinuation
- 2004-04-23 AR ARP040101388A patent/AR044075A1/es unknown
- 2004-04-23 EP EP10179435.2A patent/EP2308828A3/en not_active Withdrawn
- 2004-04-23 HR HR20100042T patent/HRP20100042T1/hr unknown
- 2004-04-23 TW TW093111360A patent/TWI329628B/zh not_active IP Right Cessation
- 2004-04-23 JP JP2005505801A patent/JP3751312B2/ja not_active Expired - Lifetime
- 2004-04-23 RU RU2005123985/04A patent/RU2315036C2/ru not_active IP Right Cessation
- 2004-04-23 AU AU2004232604A patent/AU2004232604C1/en not_active Ceased
- 2004-04-23 ES ES04729243T patent/ES2337576T3/es not_active Expired - Lifetime
- 2004-04-23 ZA ZA200505587A patent/ZA200505587B/en unknown
- 2004-04-23 NZ NZ541188A patent/NZ541188A/en not_active IP Right Cessation
- 2004-04-23 DK DK04729243.8T patent/DK1619180T3/da active
- 2004-04-23 CN CN200480002843A patent/CN100577633C/zh not_active Expired - Fee Related
- 2004-04-23 DE DE602004024668T patent/DE602004024668D1/de not_active Expired - Lifetime
- 2004-04-23 CN CN200910253477A patent/CN101723921A/zh active Pending
- 2004-04-23 PL PL04729243T patent/PL1619180T3/pl unknown
- 2004-04-23 EP EP09177717A patent/EP2189439A3/en not_active Withdrawn
-
2005
- 2005-07-07 IL IL169575A patent/IL169575A/en not_active IP Right Cessation
- 2005-10-19 CO CO05106148A patent/CO5640091A2/es active IP Right Grant
- 2005-10-21 NO NO20054868A patent/NO20054868L/no not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/840,739 patent/US20080255042A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,964 patent/US20090326058A1/en not_active Abandoned
-
2010
- 2010-03-10 CY CY20101100234T patent/CY1109880T1/el unknown
-
2011
- 2011-12-23 US US13/336,205 patent/US20120301552A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044075A1 (es) | Antagonista de un receptor sensible al calcio | |
| PE20030808A1 (es) | Derivados triciclicos heterociclicos como antagonistas receptores de trombina | |
| AR059280A1 (es) | Compuestos heterociclicos que contienen nitrogeno | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
| PE20061297A1 (es) | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c | |
| AR035068A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR061946A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas | |
| AR035349A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
| AR035369A1 (es) | Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos | |
| PE20091408A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| ECSP13012771A (es) | Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos | |
| NI200600262A (es) | 4-fenilamino-quinazolin-6-il-amidas. | |
| AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
| AR025975A1 (es) | Compuestos quimicos. | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| PE20080038A1 (es) | Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa | |
| PE20081492A1 (es) | Derivados de sulfonamida heterociclicos como antagonista de edg-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |